Patient characteristics at baseline
| Parameter | All patients, N=90 | With AKI, N=49 | Without AKI, N=41 |
| Male:female | 64:26 | 33:16 | 31:10 |
| Age (years) | 55.8±0.8 | 54.5±1.2 | 56.2±1.4 |
| Aetiology | |||
| Alcoholic cirrhosis | 49 | 25 | 24 |
| Viral | 27 | 15 | 12 |
| Others | 14 | 9 | 5 |
| Heart rate (beats/min) | 72±4 | 73±3 | 70±5 |
| Mean arterial pressure (mm Hg) | 89±3 | 89±3 | 89±3 |
| Serum sodium (135–145 mmol/l) | 134±1 | 134±1 | 135±1 |
| Serum potassium (3.5–5.5 mmol/l) | 4.1±0.1 | 4.1±0.1 | 4.0±0.1 |
| Serum creatinine (<110 μmol/l) | 72±2 | 74±2 | 68±2 |
| AST (<35 IU/l) | 59±4 | 55±3 | 63±8 |
| ALT (<40 IU/l) | 33±2 | 33±3 | 33±4 |
| ALP (<110 IU/l) | 133±7 | 133±11 | 132±11 |
| Bilirubin (<17 μmol/l) | 50±4 | 48±6 | 53±7 |
| Albumin (35–50 g/l) | 33±1 | 33±1 | 33±1 |
| Haemoglobin (130-170 g/l) | 119±2 | 116±3 | 121±3 |
| Platelet count (150–400×109/l) | 127±9 | 124±11 | 128±15 |
| INR (<1.0) | 1.46±0.04 | 1.48±0.06 | 1.46±0.06 |
| Child–Pugh score | 8.8±0.2 | 8.6±0.2 | 8.8±0.2 |
| Child–Pugh class (B/C) | 67/23 | 36/13 | 31/10 |
| MELD score | 11±1 | 11±1 | 11±1 |
| Comorbidities | |||
| Diabetes mellitus | 16 | 9 | 7 |
| Systemic hypertension | 9 | 5 | 4 |
| Mode of decompensation | |||
| Ascites | 90 | 49 | 41 |
| History of variceal bleed | 28 | 15 | 13 |
| History of encephalopathy | 31 | 19 | 12 |
| Coagulopathy | 23 | 14 | 9 |
| History of spontaneous bacterial peritonitis | 9 | 2 | 7 |
| Diuretic use (no of patients) | 81 | 43 | 38 |
| Diuretic doses (no of patients/mean dose) | |||
| Spironolactone | 62/110 mg | 36/116 mg | 26/101 mg |
| Amiloride | 16/15 mg | 9/16 mg | 7/14 mg |
| Furosemide | 71/58 mg | 40/60 mg | 31/58 mg |
| Antibiotic use | |||
| Ciprofloxacin | 8 | 2 | 6 |
| Norfloxacin | 1 | 0 | 1 |
| Proteinuria (<0.3 g/l) | 5 | 5 | 0 |
There is no significant difference in any baseline parameter between the AKI and non-AKI groups. Normal values are given in parentheses.
AKI, acute kidney injury; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; INR, international normalised ratio; MELD, model for end-stage liver disease.